Se connecter

Bibliographies thématiques / ATP-competitive

Sommaire

Articles de revues
Thèses
Chapitres de livres
Actes de conférences
Rapports d'organisations

Littérature scientifique sur le sujet « ATP-competitive »

Auteur : Grafiati

Publié le 1 avril 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « ATP-competitive ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "ATP-competitive"

1

Lebakken, Connie S., Laurie J. Reichling, Jason M. Ellefson et Steven M. Riddle. « Detection of Allosteric Kinase Inhibitors by Displacement of Active Site Probes ». Journal of Biomolecular Screening 17, n^o 6 (26 mars 2012) : 813–21. http://dx.doi.org/10.1177/1087057112439889.

Texte intégral

Résumé :

Non–adenosine triphosphate (ATP) competitive, allosteric inhibitors provide a promising avenue to develop highly selective small-molecule kinase inhibitors. Although this class of compounds is growing, detection of such inhibitors can be challenging as standard kinase activity assays preferentially detect compounds that bind to active kinases in an ATP competitive manner. We have previously described a time-resolved fluorescence resonance energy transfer (TR-FRET)–based kinase binding assay using the competitive displacement of ATP competitive active site fluorescent probes (“tracers”). Although this format has gained acceptance, published data with this and related formats are almost entirely without examples of non-ATP competitive compounds. Thus, this study addresses whether this format is useful for non-ATP competitive inhibitors. To this end, 15 commercially available non-ATP competitive inhibitors were tested for their ability to displace ATP competitive probes. Despite the diversity of both compound structures and their respective targets, 14 of the 15 compounds displaced the tracers with IC50 values comparable to literature values. We conclude that such binding assays are well suited for the study of non-ATP competitive inhibitors. In addition, we demonstrate that allosteric inhibitors of BCR-Abl and MEK bind preferentially to the nonphosphorylated (i.e., inactive) form of the kinase, indicating that binding assays may be a preferred format in some cases.

Styles APA, Harvard, Vancouver, ISO, etc.

2

Agius, Michael P., Kristin Ko, Taylor K. Johnson, Sameer Phadke et Matthew B. Soellner. « Conformation-tunable ATP-competitive kinase inhibitors ». Chemical Communications 58, n^o 21 (2022) : 3541–44. http://dx.doi.org/10.1039/d1cc06893h.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Garuti, L., M. Roberti et G. Bottegoni. « Non-ATP Competitive Protein Kinase Inhibitors ». Current Medicinal Chemistry 17, n^o 25 (1 septembre 2010) : 2804–21. http://dx.doi.org/10.2174/092986710791859333.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Lee, Byung-Il, Hyung-Jun Ahn, Ki-Cheol Han, Dae-Ro Ahn et Dong-Yun Shin. « Pyrogallin, an ATP-Competitive Inhibitor of JAK3 ». Bulletin of the Korean Chemical Society 32, n^o 3 (20 mars 2011) : 1077–79. http://dx.doi.org/10.5012/bkcs.2011.32.3.1077.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Schenone, S., C. Brullo, F. Musumeci, M. Radi et M. Botta. « ATP-Competitive Inhibitors of mTOR : An Update ». Current Medicinal Chemistry 18, n^o 20 (1 juillet 2011) : 2995–3014. http://dx.doi.org/10.2174/092986711796391651.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Lazaro, Glorianne, Eleftherios Kostaras et Igor Vivanco. « Inhibitors in AKTion : ATP-competitive vs allosteric ». Biochemical Society Transactions 48, n^o 3 (26 mai 2020) : 933–43. http://dx.doi.org/10.1042/bst20190777.

Texte intégral

Résumé :

Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target. Multiple AKT inhibitors, broadly classified as either ATP-competitive or allosteric, are currently in various stages of clinical development. Herein, we review the evidence for AKT dependence in human tumours and focus on its therapeutic targeting by the two drug classes. We highlight the future prospects for the development and implementation of more effective context-specific AKT inhibitors aided by our increasing knowledge of both its regulation and some previously unrecognised non-canonical functions.

Styles APA, Harvard, Vancouver, ISO, etc.

7

Parrish, Cynthia A., Nicholas D. Adams, Kurt R. Auger, Joelle L. Burgess, Jeffrey D. Carson, Amita M. Chaudhari, Robert A. Copeland et al. « Novel ATP-Competitive Kinesin Spindle Protein Inhibitors ». Journal of Medicinal Chemistry 50, n^o 20 (octobre 2007) : 4939–52. http://dx.doi.org/10.1021/jm070435y.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Ito, Masahiro, Misa Iwatani, Yusuke Kamada, Satoshi Sogabe, Shoichi Nakao, Toshio Tanaka, Tomohiro Kawamoto, Samuel Aparicio, Atsushi Nakanishi et Yasuhiro Imaeda. « Discovery of selective ATP-competitive eIF4A3 inhibitors ». Bioorganic & ; Medicinal Chemistry 25, n^o 7 (avril 2017) : 2200–2209. http://dx.doi.org/10.1016/j.bmc.2017.02.035.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Zarębska, Ewa A., Krzysztof Kusy, Ewa M. Słomińska, Łukasz Kruszyna et Jacek Zieliński. « Plasma Nucleotide Dynamics during Exercise and Recovery in Highly Trained Athletes and Recreationally Active Individuals ». BioMed Research International 2018 (9 octobre 2018) : 1–11. http://dx.doi.org/10.1155/2018/4081802.

Texte intégral

Résumé :

Circulating plasma ATP is able to regulate local skeletal muscle blood flow and 02 delivery causing considerable vasodilatation during exercise. We hypothesized that sport specialization and specific long-term training stimuli have an impact on venous plasma [ATP] and other nucleotides concentration. Four athletic groups consisting of sprinters (n=11; age range 21–30 yr), endurance-trained athletes (n=16; age range 18–31 yr), futsal players (n=14; age range 18–30 yr), and recreationally active individuals (n=12; age range 22–33 yr) were studied. Venous blood samples were collected at rest, during an incremental treadmill test, and during recovery. Baseline [ATP] was 759±80 nmol·l−1 in competitive athletes and 680±73 nmol·l−1 in controls and increased during exercise by ~61% in competitive athletes and by ~31% in recreationally active participants. We demonstrated a rapid increase in plasma [ATP] at exercise intensities of 83–87% of VO2max in competitive athletes and 94% in controls. Concentrations reported after 30 minutes of recovery were distinct from those obtained preexercise in competitive athletes (P<0.001) but not in controls (P=0.61). We found a correlation between total-body skeletal muscle mass and resting and maximal plasma [ATP] in competitive athletes (r=0.81 and r=0.75, respectively). In conclusion, sport specialization is significantly related to plasma [ATP] at rest, during exercise, and during maximal effort. Intensified exercise-induced plasma [ATP] increases may contribute to more effective vessel dilatation during exercise in highly trained athletes than in recreational runners. The most rapid increase in ATP concentration was associated with the respiratory compensation point. No differences between groups of competitive athletes were observed during the recovery period suggesting a similar pattern of response after exercise. Total-body skeletal muscle mass is indirectly related to plasma [ATP] in highly trained athletes.

Styles APA, Harvard, Vancouver, ISO, etc.

10

Lyle, S., D. H. Geller, K. Ng, J. Stanczak, J. Westley et N. B. Schwartz. « Kinetic mechanism of adenosine 5′-phosphosulphate kinase from rat chondrosarcoma ». Biochemical Journal 301, n^o 2 (15 juillet 1994) : 355–59. http://dx.doi.org/10.1042/bj3010355.

Texte intégral

Résumé :

Biosynthesis of the activated sulphate donor adenosine 3′-phosphate 5′-phosphosulphate (PAPS) involves the sequential action of two enzyme activities. ATP-sulphurylase catalyses the formation of APS (adenosine 5′-phosphosulphate) from ATP and free sulphate, and APS is then phosphorylated by APS kinase to produce PAPS. Initial-velocity patterns for rat chondrosarcoma APS kinase indicate a single-displacement formal mechanism with KmAPS 76 nM and KmATP = 24 microM. Inhibition studies using analogues of substrates and products were carried out to determine the reaction mechanism. An analogue of PAPS, adenosine 3′-phosphate 5′-[beta-methylene]phosphosulphate, exhibited competitive inhibition with APS and non-competitive inhibition with ATP. An analogue of APS, adenosine 5′-[beta-methylene]phosphosulphate was also competitive with APS and non-competitive with ATP. Adenosine 5′-[beta gamma-imido]triphosphate showed competitive inhibition with respect to ATP and produced mixed-type inhibition, with a pronounced intercept effect and a small slope effect, with respect to APS. These results are in accord with the formulation of the predominant pathway as a steady-state ordered mechanism with APS as the leading substrate and PAPS as the final product released.

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "ATP-competitive"

1

Morgan, R. M. L. « ATP-competitive inhibitors as antifungals : Targeting the spectoria triticic kinome ». Thesis, University of Oxford, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.531991.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Mazaideh, Ghassab M. A. Al Verfasser], Wolfgang [Akademischer Betreuer] Sippl, Peter [Akademischer Betreuer] [Imming et Manfred [Akademischer Betreuer] Jung. « Development and synthesis of new potential ATP-Competitive Myt1 Kinase inhibitors / Ghassab M. A. Al-Mazaideh. Betreuer : Wolfgang Sippl ; Peter Imming ; Manfred Jung ». Halle, Saale : Universitäts- und Landesbibliothek Sachsen-Anhalt, 2012. http://d-nb.info/1025303652/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Driscoll, Brandon. « Modulation of TGF‐β Receptor 1 signalling in Live Cells ». Thesis, 2009. http://hdl.handle.net/1807/17505.

Texte intégral

Résumé :

TGF-β negatively affects the maintenance and expansion of hematopoietic stem cells ex vivo and its inhibition has been widely studied as a treatment for numerous hematopoietic disorders and cancers. Current inhibitory strategies (small molecule ATP competitors and neutralizing antibodies) are compared to a novel cell-permeable peptide-based inhibitor of TGF-β RI. Multiple levels of assay from biochemical to functional are utilized with the aim of applying the most successful inhibitor to hematopoietic stem cell culture. The neutralizing antibody proved ineffective in the short-term biochemical assay but was extremely effective at neutralizing TGF-β signalling in proliferation and hematopoietic colony-forming cell assays with no evidence of toxicity. The small molecule inhibitors (SD-208 and Pyrazole TGF-β RI inhibitor) were equally effective at micromolar levels in all forms of assay, with SD-208 being slightly more potent. The novel peptide inhibitor proved ineffective in all assays, which is likely a result of its rapid degradation in live cells.

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "ATP-competitive"

1

Liu, Qingsong, Seong A. Kang, Carson C. Thoreen, Wooyoung Hur, Jinhua Wang, Jae Won Chang, Andrew Markhard et al. « Development of ATP-Competitive mTOR Inhibitors ». Dans Methods in Molecular Biology, 447–60. Totowa, NJ : Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-430-8_29.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Register, Ames C., Sujata Chakraborty et Dustin J. Maly. « Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors ». Dans Methods in Molecular Biology, 79–89. New York, NY : Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7154-1_6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Salomon, Dor, Chao Zhang, Kevan M. Shokat et Guido Sessa. « Sensitizing Plant Protein Kinases to Specific Inhibition by ATP-Competitive Molecules ». Dans Methods in Molecular Biology, 185–97. Totowa, NJ : Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-264-9_10.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

McInnes, Campbell. « REPLACE Strategy for Generating Non-ATP-Competitive Inhibitors of Cell Cycle Protein Kinases ». Dans Protein-Protein Interactions in Drug Discovery, 291–304. Weinheim, Germany : Wiley-VCH Verlag GmbH & Co. KGaA, 2013. http://dx.doi.org/10.1002/9783527648207.ch12.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Clausen, Johannes D., David B. McIntosh, David G. Woolley et Jens Peter Andersen. « Determination of the ATP Affinity of the Sarcoplasmic Reticulum Ca2+-ATPase by Competitive Inhibition of [γ-32P]TNP-8N3-ATP Photolabeling ». Dans P-Type ATPases, 233–59. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3179-8_22.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Yu, Ker, et Lourdes Toral-Barza. « Biochemical and Pharmacological Inhibition of mTOR by Rapamycin and an ATP-Competitive mTOR Inhibitor ». Dans Methods in Molecular Biology, 15–28. Totowa, NJ : Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-430-8_2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Rea, Delphine. « Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia ». Dans Hematologic Malignancies, 77–91. Cham : Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71913-5_6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Rea, Delphine. « Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia ». Dans Hematologic Malignancies, 71–87. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-33198-0_5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Sarvagalla, Sailu, et Mohane Selvaraj Coumar. « Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase ». Dans Pharmaceutical Sciences, 1115–43. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-1762-7.ch043.

Texte intégral

Résumé :

Most of the developed kinase inhibitor drugs are ATP competitive and suffer from drawbacks such as off-target kinase activity, development of resistance due to mutation in the ATP binding pocket and unfavorable intellectual property situations. Besides the ATP binding pocket, protein kinases have binding sites that are involved in Protein-Protein Interactions (PPIs); these PPIs directly or indirectly regulate the protein kinase activity. Of recent, small molecule inhibitors of PPIs are emerging as an alternative to ATP competitive agents. Rational design of inhibitors for kinase PPIs could be carried out using molecular modeling techniques. In silico tools available for the prediction of hot spot residues and cavities at the PPI sites and the means to utilize this information for the identification of inhibitors are discussed. Moreover, in silico studies to target the Aurora B-INCENP PPI sites are discussed in context. Overall, this chapter provides detailed in silico strategies that are available to the researchers for carrying out structure-based drug design of PPI inhibitors.

Styles APA, Harvard, Vancouver, ISO, etc.

10

Sarvagalla, Sailu, et Mohane Selvaraj Coumar. « Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase ». Dans Advances in Medical Technologies and Clinical Practice, 249–77. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-5225-0362-0.ch010.

Texte intégral

Résumé :

Most of the developed kinase inhibitor drugs are ATP competitive and suffer from drawbacks such as off-target kinase activity, development of resistance due to mutation in the ATP binding pocket and unfavorable intellectual property situations. Besides the ATP binding pocket, protein kinases have binding sites that are involved in Protein-Protein Interactions (PPIs); these PPIs directly or indirectly regulate the protein kinase activity. Of recent, small molecule inhibitors of PPIs are emerging as an alternative to ATP competitive agents. Rational design of inhibitors for kinase PPIs could be carried out using molecular modeling techniques. In silico tools available for the prediction of hot spot residues and cavities at the PPI sites and the means to utilize this information for the identification of inhibitors are discussed. Moreover, in silico studies to target the Aurora B-INCENP PPI sites are discussed in context. Overall, this chapter provides detailed in silico strategies that are available to the researchers for carrying out structure-based drug design of PPI inhibitors.

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "ATP-competitive"

1

Mueller, Daniel, Frank Totzke, Thomas Weber, Carolin Heidemann-Dinger, Constance Ketterer, Diane Krämer, Marcel Pathe et Michael H. Kubbutat. « Abstract 4186 : A biochemical approach to discriminate between ATP-competitive and non-ATP competitive protein kinase inhibitors ». Dans Proceedings : AACR Annual Meeting 2017 ; April 1-5, 2017 ; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4186.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Estes, Kara, Zhengguan Yang, Campbell McInnes et Michael D. Wyatt. « Abstract 3240 : Development of non-ATP competitive, PLK1 selective inhibitors ». Dans Proceedings : AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011 ; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3240.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Rana, Sandeep, Elizabeth Blowers et Amarnath Natarajan. « Abstract 3645 : A non-ATP competitive IKKβ inhibitor for cancer therapy ». Dans Proceedings : AACR 106th Annual Meeting 2015 ; April 18-22, 2015 ; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3645.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Schio, Laurent, Conception Nemecek, Antonio Ugolini, Sylvie Wentzler, Sandrine Grapinet, Jean Khider, Eva Albert et al. « Abstract 2911 : SAR125844 : a potent and selective ATP-competitive inhibitor of MET kinase ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2911.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Lin, Kui. « Abstract DDT02-01 : GDC-0068 : A novel, selective, ATP-competitive inhibitor of Akt ». Dans Proceedings : AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011 ; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-ddt02-01.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Zimmerman, Kristin M., Brian Lee, Wei-Jen Chung, Florian Gnad, Eva Lin, Scott Martin et Kui Lin. « Abstract LB-115 : Mechanisms of acquired resistance to allosteric versus ATP-competitive AKT inhibition ». Dans Proceedings : AACR 107th Annual Meeting 2016 ; April 16-20, 2016 ; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-115.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Tandon, Manuj, James Johnson, Elisa Farber, Evan Carder, Peter Wipf et Qiming J. Wang. « Abstract 2182 : Novel ATP-competitive protein kinase D inhibitors : in vitro characterization and SAR analysis. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2182.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Luke, Richard W., Matthew Addie, Matthew R. Box, David Buttar, Claire Crafter, Gordon S. Currie, Sabina C. Cosulich et al. « Abstract 4478 : Discovery of AZD5363, an orally bioavailable, potent ATP-competitive inhibitor of AKT kinases ». Dans Proceedings : AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011 ; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4478.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Dai, Yao, et Dietmar W. Siemann. « Abstract 3761 : Efficacy of the ATP-competitive mTOR inhibitor AZD8055 in PTEN-wild type cancer cells ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3761.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Sootome, Hiroshi, Suzuko Kato, Masanori Kato et Hiroshi Hirai. « Abstract 1117 : Acquired resistance to ATP-competitive and irreversible FGFR inhibitors (FGFRi's) : A library-based approach ». Dans Proceedings : AACR Annual Meeting 2021 ; April 10-15, 2021 and May 17-21, 2021 ; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1117.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "ATP-competitive"

1

Reddy, E. P. A Non-ATP Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant Cmls. Fort Belvoir, VA : Defense Technical Information Center, mai 2008. http://dx.doi.org/10.21236/ada487510.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Reddy, E. P. ON012380 : A Non-ATP Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs. Fort Belvoir, VA : Defense Technical Information Center, mai 2010. http://dx.doi.org/10.21236/ada532978.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Reddy, E. P. ON012380 : A Non-ATP Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs. Fort Belvoir, VA : Defense Technical Information Center, mai 2009. http://dx.doi.org/10.21236/ada510718.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!